TCV Trust & Wealth Management Inc. Reduces Position in Becton, Dickinson and Company (NYSE:BDX)

TCV Trust & Wealth Management Inc. trimmed its position in Becton, Dickinson and Company (NYSE:BDX) by 9.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,096 shares of the medical instruments supplier’s stock after selling 217 shares during the quarter. TCV Trust & Wealth Management Inc.’s holdings in Becton, Dickinson and Company were worth $476,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its holdings in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 877 shares during the last quarter. E. Ohman J or Asset Management AB boosted its holdings in shares of Becton, Dickinson and Company by 13.4% during the fourth quarter. E. Ohman J or Asset Management AB now owns 176,097 shares of the medical instruments supplier’s stock worth $39,951,000 after purchasing an additional 20,859 shares during the period. Arete Wealth Advisors LLC bought a new stake in shares of Becton, Dickinson and Company in the third quarter worth about $767,000. Busey Bank increased its holdings in Becton, Dickinson and Company by 3.8% during the 4th quarter. Busey Bank now owns 66,255 shares of the medical instruments supplier’s stock valued at $15,031,000 after purchasing an additional 2,399 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in Becton, Dickinson and Company by 79.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock valued at $720,089,000 after purchasing an additional 1,317,723 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Stock Down 0.0 %

BDX stock opened at $229.50 on Wednesday. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $251.99. The company has a market capitalization of $66.56 billion, a price-to-earnings ratio of 38.12, a price-to-earnings-growth ratio of 1.65 and a beta of 0.40. The business’s 50 day moving average price is $232.20 and its two-hundred day moving average price is $233.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.13.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. As a group, analysts forecast that Becton, Dickinson and Company will post 14.41 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be paid a $1.04 dividend. The ex-dividend date is Monday, March 10th. This represents a $4.16 annualized dividend and a dividend yield of 1.81%. Becton, Dickinson and Company’s payout ratio is 69.10%.

Becton, Dickinson and Company announced that its board has authorized a share repurchase plan on Tuesday, January 28th that permits the company to buyback 10,000,000 shares. This buyback authorization permits the medical instruments supplier to purchase shares of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board believes its shares are undervalued.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Piper Sandler lifted their price objective on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 28th. StockNews.com lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $283.00.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Roland Goette sold 4,483 shares of the firm’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $221.01, for a total transaction of $990,787.83. Following the completion of the transaction, the executive vice president now owns 24,345 shares of the company’s stock, valued at $5,380,488.45. This trade represents a 15.55 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jeffrey William Henderson bought 1,500 shares of the company’s stock in a transaction on Monday, February 10th. The stock was bought at an average cost of $233.62 per share, for a total transaction of $350,430.00. Following the completion of the acquisition, the director now directly owns 8,015 shares of the company’s stock, valued at approximately $1,872,464.30. This represents a 23.02 % increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 9,844 shares of company stock valued at $2,210,716 in the last three months. Company insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.